GET DAILY SIGNALSGilead Sciences (GILD) Reports +6.8% Revenue Growth in Q3 as HIV Franchise Accelerates
Key Takeaways
- Total revenue reached $8.3 billion, up 6.8% year over year and above the roughly $7.81 billion consensus estimate.
- Non-GAAP (adjusted) diluted earnings per share came in at $2.55, a 16.2% beat versus the approximately $2.19 consensus, and up 3% from $2.47 a year ago.
- GAAP diluted EPS fell to $1.94 from $2.43, pressured by net losses from equity securities and higher operating expenses.
- Gilead's HIV franchise grew 18% year over year, while HIV prevention sales nearly doubled, driving what management called its strongest base-business growth in more than a decade.
- The company raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion.
Earnings Context and Why It Matters
Gilead Sciences stands as a biopharmaceutical leader, best known for its HIV franchise built around Biktarvy and Descovy, with an expanding oncology and inflammation portfolio alongside. This third-quarter report carries particular weight because it shows whether the company can maintain durable growth beyond its established HIV base. From what I see, investors are focused on momentum in newer offerings such as Trodelvy and Livdelzi, along with the path for HIV prevention products. The quarter also unfolded against increasing attention to drug pricing, including the Centers for Medicare and Medicaid Services finalizing a Maximum Fair Price for Biktarvy that begins in 2028. Strong execution here provides a clearer picture of Gilead's longer-term diversification efforts.
Reported Results
For the third quarter of 2026, ended September 30, GILD reported total revenue of $8.3 billion, a 6.8% rise from $7.77 billion a year earlier and ahead of the roughly $7.81 billion Wall Street consensus. Product sales increased 13% to $8.29 billion, and excluding the COVID-19 treatment Veklury, product sales advanced 16% year over year. GAAP diluted EPS declined to $1.94 from $2.43, reflecting net losses from equity securities and higher operating costs, while non-GAAP diluted EPS rose 3% to $2.55 from $2.47. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The HIV franchise grew 18% to about $6.2 billion, with prevention sales nearly doubling. Biktarvy sales were roughly flat at about $4.1 billion, while Trodelvy sales rose 42% to an approximately $2 billion annual run rate. Product gross margin improved to 81.0% from 78.6%. Gilead raised full-year 2026 product sales guidance to $31.0 billion to $31.3 billion, though it widened its non-GAAP EPS outlook to a loss of $1.20 to $0.85 per share, driven largely by acquisition-related and other non-cash items.
Market Reaction and Investor Sentiment
GILD shares ended the regular session up 4.0% at $165.61 ahead of the release, then added roughly 1.8% in after-hours trading as investors digested the top- and bottom-line beats. The market appeared to reward the 6.3% revenue beat and the 16.2% non-GAAP EPS beat, as well as the upward revision to full-year product sales guidance. Still, sentiment remains tempered by the wider full-year non-GAAP loss forecast and the near-flat performance of Biktarvy, the company's single largest product. Net-net, the reaction suggests investors are focusing on the accelerating base-business growth rather than the near-term accounting headwinds.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several catalysts tied to Gilead's diversification strategy. The company expects to file its investigational once-weekly oral HIV regimen, ISL/LEN, before year-end, and a potential approval decision for the cell therapy anito-cel is expected around the end of 2026. These pipeline milestones could meaningfully shape the company's longer-term growth narrative beyond Biktarvy.
In inflammation, Gilead plans to advance emvistegrast into Phase 3 studies for ulcerative colitis in 2027, backed by positive Phase 2 data. The company has also broadened its pipeline through acquisitions, including an oral IL-23 receptor inhibitor program, signaling continued investment in a third strategic therapeutic area alongside HIV and oncology.
On the policy front, the finalized Maximum Fair Price for Biktarvy under Medicare will begin affecting revenue on January 1, 2028, creating a medium-term headwind to monitor. Meanwhile, investors should track whether HIV prevention products such as Yeztugo and Descovy for PrEP (pre-exposure prophylaxis) sustain their rapid uptake, and whether Trodelvy maintains its momentum across breast cancer indications. Margin trends and the pace of operating-expense growth will also remain important signals of disciplined execution.
Exploring AI Tools for Earnings Analysis
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals have become useful for tracking how earnings surprises translate into price action over time. I find they help surface patterns across similar healthcare names when I am reviewing quarterly results like these. This approach keeps the focus on data-driven comparisons rather than isolated headlines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 59 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 36 of 55 cases over the following month. The odds of a continued upward trend are 65%.
Following a +0.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 217 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 126 of 266 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.689) is normal, around the industry mean (-2.729). GILD's P/E Ratio (-60.996) is considerably lower than the industry average of (20.997). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.040) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement